Adjuvant trastuzumab for breast cancer - Assessing HER2/neu status incurs more costs for treatment

被引：5
作者：
Kell, MR [1 ]
Power, CP [1 ]
机构：
[1] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dublin, Ireland
来源：
BRITISH MEDICAL JOURNAL | 2005年 / 331卷 / 7526期
关键词：
D O I：
10.1136/bmj.331.7526.1202
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1202 / 1202
页数：1
相关论文
共 3 条
  • [1] Adjuvant trastuzumab for breast cancer - We need to ensure that equity exists for access to effective and expensive treatments
    Dent, R
    Clemons, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7524): : 1035 - 1036
  • [2] Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
    Press, MF
    Sauter, G
    Bernstein, L
    Villalobos, IE
    Mirlacher, M
    Zhou, JY
    Wardeh, R
    Li, YT
    Guzman, R
    Ma, YL
    Sullivan-Halley, J
    Santiago, A
    Park, JM
    Riva, A
    Slamon, DJ
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (18) : 6598 - 6607
  • [3] The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy (Publication with Expression of Concern)
    Ross, JS
    Fletcher, JA
    Linette, GP
    Stec, J
    Clark, E
    Ayers, M
    Symmans, WF
    Pusztai, L
    Bloom, KJ
    [J]. ONCOLOGIST, 2003, 8 (04) : 307 - 325
1